New Breakthrough Therapy Designation Has Potential to Shorten Development Time Considerably, According to the Tufts Center for the Study of Drug Development
January 23, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 23, 2014) - The recently launched Breakthrough Therapy Designation (BTD) program in the United States, aimed at expediting development and review of drugs intended to...
Hemispherx Presents New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
January 21, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University will present a research paper on January 21,...
Drug Developers Are Implementing New Strategies for Use of Comparator Drugs in Clinical Trials, According to Tufts Center for the Study of Drug Development
January 16, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 16, 2014) - Drug developers are aggressively implementing new strategies to improve their access to and use of comparator drugs, which are used in clinical trials to...
Drug Company Success Depends on New Development Paradigms, According to Tufts Center for the Study of Drug Development
January 07, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 7, 2014) - While many drug developers continue to improve clinical trial operational efficiency to increase the pace of new product introductions, their medium- and...
Matrix Medical Network Annually Recognizes Nurse Practitioner Excellence With NP3 Award
December 12, 2013 11:03 ET
|
Matrix Medical Network
SCOTTSDALE, Ariz., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Matrix Medical Network, a national leader in prospective medical assessment services for Medicare Advantage (MA) plan members and one of the...
Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically According to the Tufts Center for the Study of Drug Development
November 14, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 14, 2013) - The pharmaceutical industry, especially Big Pharma, has dramatically shifted its R&D focus from its historical concentration on small molecule drugs...
Drug Sponsors and Their External Service Partners Say Adjusting Relationship Models Offers a Path to Greater Performance and Efficiency, According to Tufts Center for the Study of Drug Development
October 08, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Oct 8, 2013) - While drug sponsor use of strategic relationships with contract service providers has increased dramatically during the past five years, improvements in...
Clinical Study Failures Vary Widely by Phase of Study and Therapeutic Class, According to the Tufts Center for the Study of Drug Development
September 10, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 10, 2013) - While lack of commercial viability is the leading cause of Phase I failures for new drug candidates, efficacy issues dominate as the reason for Phase II...
How To Leverage New Technologies To Succeed In A Consumer-Centric Healthcare Environment -- Topic Of New Executive Web Briefing From Netsmart & OPEN MINDS
August 16, 2013 17:06 ET
|
Open Minds
GETTYSBURG, Pa., Aug. 16, 2013 (GLOBE NEWSWIRE) -- Free Registration Link: http://www.openminds.com/events/webinar-082113-clinicalit.htm
OPEN MINDS and Netsmart have announced a new...
CoCENTRIX to Present Clinical Best Practices for Behavioral Health Providers in "Discharge Planning: Best Practices for a Safe & Accountable Transition of Care"
August 15, 2013 17:20 ET
|
Open Minds
GETTYSBURG, Pa., Aug. 15, 2013 (GLOBE NEWSWIRE) -- OPEN MINDS and CoCENTRIX have announced a new executive web briefing specifically designed to help behavioral health and human service provider...